The European Commission is set to investigate the effects of the US’s most-favored-nation (MFN) drug pricing policy, initiated by former President Trump. This policy aims to align US drug prices with those of other developed nations, potentially leading to significant changes in the pharmaceutical market.
Since the introduction of the MFN policy, drug launches in the EU have reportedly dropped by 35%. This decline raises concerns about delayed access to innovative medicines for European patients, as pharmaceutical companies may prioritize higher revenues from the US market over launching new products in Europe.
Health ministers are particularly interested in understanding how this pricing strategy affects the availability and affordability of drugs in the EU. They are seeking clarity on whether the MFN policy will lead to increased prices or even cause some companies to withdraw from the European market altogether.
The urgency of this investigation is underscored by the need for timely answers, with the European Health Commissioner aiming to complete the assessment before summer. The findings could have lasting implications for healthcare access across Europe, highlighting the interconnectedness of global pharmaceutical policies.
Source: Euronews
